Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder

a meta-analysis

Clayton, Anita H.a,*; Hwang, Eunheeb,*; Kornstein, Susan G.c; Tourian, Karen A.b; Cheng, Ru-fongb; Abraham, Lucyd; Mele, Lindab; Boucher, Matthieue

International Clinical Psychopharmacology: November 2015 - Volume 30 - Issue 6 - p 307–315
doi: 10.1097/YIC.0000000000000094
ORIGINAL ARTICLES
Buy
SDC

The primary objective of this post-hoc analysis was to evaluate the effect of short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual Experiences Scale scores, in adult outpatients with major depressive disorder. Data from three randomized, double-blind, placebo-controlled trials of 50 or 100 mg/day desvenlafaxine for major depressive disorder were pooled. SD status, determined from Arizona Sexual Experiences Scale scores, was assessed at baseline and week 8, last observation carried forward. Subgroup analyses addressed the effects of sex, baseline SD, and antidepressant response. At week 8, last observation carried forward (n=1562), SD rates were 54, 47, and 49% for 50 mg/day desvenlafaxine, 100 mg/day desvenlafaxine, and placebo, respectively [adjusted odds ratios (95% confidence interval) vs. placebo: 1.205 (0.928, 1.564) and 1.129 (0.795, 1.604), respectively]. The treatment by baseline SD interaction approached statistical significance (P=0.0663), mainly driven by poorer scores for desvenlafaxine versus placebo in the 100 mg group. Treatment by sex interactions were not statistically significant. Small but statistically significant treatment by sex interactions were observed for sex drive (P=0.0011) and ease of erection/lubrication (P=0.0151). Although there was no overall effect of desvenlafaxine on SD, a treatment by baseline SD interaction was suggested for 100 mg desvenlafaxine.

aDepartment of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville

bPfizer Inc., Collegeville, Pennsylvania

cDepartment of Psychiatry and Institute for Women's Health, Virginia Commonwealth University, Richmond, Virginia, USA

dPfizer Inc., Walton Oaks, UK

ePfizer Canada Inc., Kirkland, Quebec, Canada

* Anita H. Clayton and Eunhee Hwang contributed equally to the writing of this article.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.intclinpsychopharm.com).

Clinical trial registration: http://www.clinicaltrials.gov, NCT00798707, NCT00863798, NCT01432457.

Correspondence to Anita H. Clayton, MD, University of Virginia Health System, P.O. Box 800623, Charlottesville, VA 22908-0623, USA Tel: +1 4340 243 4646; fax: +1 4340 243 4743; e-mail: ahc8v@virginia.edu

Received March 2, 2015

Accepted June 25, 2015

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.